

11 February 2022

Acquisition of API – ACCC clearance

Wesfarmers today announced that it has received confirmation from the Australian Competition and Consumer Commission (ACCC) that it will not oppose Wesfarmers' proposed acquisition of Australian Pharmaceutical Industries Limited (ASX:API).

Clearance from the ACCC was a condition precedent for the transaction. Subject to the satisfaction of the remaining conditions, including approval by API shareholders, completion of the transaction is expected to occur around the end of the first quarter of the 2022 calendar year.

For more information:

Media

Rebecca Keenan
Media and Public Affairs Manager
+61 8 9327 4423 or +61 402 087 055
RKeenan@wesfarmers.com.au

Investors

Simon Edmonds
Investor Relations Manager
+61 8 9327 4438 or +61 409 417 710
SEdmonds@wesfarmers.com.au

This announcement was authorised to be given to the ASX by the Wesfarmers Disclosure Committee.